ArticleFrontiers in oncology2022

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy.

Dong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.